Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Debt to Equity (2023 - 2024)

Oramed Pharmaceuticals (ORMP) has disclosed Debt to Equity for 2 consecutive years, with $0.19 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Debt to Equity changed N/A year-over-year to $0.19, compared with a TTM value of $0.19 through Mar 2024, changed N/A, and an annual FY2023 reading of $0.31, changed N/A over the prior year.
  • Debt to Equity was $0.19 for Q1 2024 at Oramed Pharmaceuticals, down from $0.31 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.51 in Q3 2023 and bottomed at $0.19 in Q1 2024.